ENDPOINTS

Exclusive: Metsera CEO on what it takes to build an obe...

Metsera, one of the few biotechs to complete an IPO this year, is making its bes...

New pharma tariffs could put generic drugmakers under p...

President Donald Trump’s threatened tariffs on pharmaceuticals are incentivizing...

Chiesi pours €430 into new Italy site; Bharat’s first C...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential ne...

Equillium says graft-versus-host drug fails Phase 3, st...

A penny stock biotech reported that its acute graft-versus-host disease drug fai...

What happened to Miga Health

My latest story is one I don’t get the chance to write often — maybe ever. W...

Nkarta to lay off 34% of staff; Savara’s debt financing...

Plus, news about Bicycle Therapeutics, Kelso Pharma, Arbutus Biopharma, Ascletis...

HHS plans to cut 10,000 more staffers in major downsizing

The Department of Health and Human Services on Thursday announced major plans to...

Miga Health co-founder shares why he turned down new fu...

Last year, Miga Health, a virtual cardiovascular care company, told investors it...

AI scribes reduce burnout, but financial returns unclea...

Despite cutting down on burnout, AI scribes have yet to clearly prove they save ...

Candel to focus on non-squamous lung cancer following n...

Candel Therapeutics said Wednesday that its viral immunotherapy prolonged surviv...

Galatea Bio gets $25M to map genetic diversity of 10 mi...

A Miami startup looking to sequence the genetic diversity of 10 million people t...

Alcon takes majority stake in Aurion, changes CEOs

Eye giant Alcon said Wednesday it acquired a majority stake in cell therapy star...

FDA approves Soleno’s rare disease drug for Prader-Will...

The FDA on Wednesday approved Soleno Therapeutics' new drug designed to treat th...

FDA critiques 'misleading' Taiho promotion of bile duct...

The FDA is taking issue with a promotional website from Taiho Oncology, alleging...

Exelixis’ cancer drug wins approval for neuroendocrine ...

The FDA has approved Exelixis' cancer drug Cabometyx to treat advanced neuroendo...

Why did radiopharma biotech Actinium hold an investor e...

Plenty of companies and CEOs have made the pilgrimage to Donald Trump's Mar-a-La...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.